Literature DB >> 17560915

A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors.

Sean Garrean1, Justin Hering, W Scott Helton, N Joseph Espat.   

Abstract

BACKGROUND: Surgical resection is the only potentially curative approach for patients with primary and metastatic liver tumors. Unfortunately, most patients with hepatic malignancy are precluded from resection due to multifocal disease, anatomic limitations, inadequate functional liver reserve, extrahepatic metastases, or medical comorbidities. Consequently, several methods of tumor ablation have been developed as alternate treatment strategies for patients with unresectable hepatic tumors or as adjuncts in total cancer therapy. The purpose of this review is to inclusively define the various ablation modalities available (transarterial, chemical, and thermal ablative), and to describe the procedures, general applications, and reported outcomes. DATA SOURCES: A MEDLINE and CINAHL search of the English-language literature was performed on transarterial, chemical, and thermal ablative therapies.
CONCLUSIONS: Presently, radiofrequency thermal ablation is the most widely applicable liver-directed modality for hepatic tumor ablation, enabling treatment of primary and metastatic tumors. However, other transarterial and thermoablative techniques are available with accumulating data for their use. Lacking at present are studies that define the role and potential benefit of the various liver-directed modalities in the treatment algorithm for hepatic tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560915     DOI: 10.1016/j.amjsurg.2006.11.025

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  10 in total

1.  Is percutaneous ethanol injection therapy still effective for hepatocellular carcinoma in the era of radiofrequency ablation?

Authors:  Jung Hyeok Kwon
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

2.  Therapy options for treatment of hepatic malignancy.

Authors:  Teresa Szyszko; Alison Brooks; Paul Tait; Domenico Rubello; Adil AL-Nahhas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

3.  Ultrasound monitoring of a novel microwave ablation (MWA) device in porcine liver: lessons learned and phenomena observed on ablative effects near major intrahepatic vessels.

Authors:  S Garrean; J Hering; A Saied; P J Hoopes; W S Helton; T P Ryan; N J Espat
Journal:  J Gastrointest Surg       Date:  2008-10-21       Impact factor: 3.452

4.  Strategies for Management of Synchronous Colorectal Metastases.

Authors:  Jason A Castellanos; Nipun B Merchant
Journal:  Curr Surg Rep       Date:  2014-06-01

Review 5.  Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update.

Authors:  Francesco Izzo; Vincenza Granata; Roberto Grassi; Roberta Fusco; Raffaele Palaia; Paolo Delrio; Gianpaolo Carrafiello; Daniel Azoulay; Antonella Petrillo; Steven A Curley
Journal:  Oncologist       Date:  2019-06-19

6.  Colorectal liver metastases; the current scenario.

Authors:  Samir Pathak; Graeme J Poston
Journal:  Indian J Surg Oncol       Date:  2011-04-19

7.  Novel laparoscopic bipolar radiofrequency energy technology for expedited hepatic tumour ablation.

Authors:  Bing Yi; Ponnandai Somasundar; N Joseph Espat
Journal:  HPB (Oxford)       Date:  2009-03       Impact factor: 3.647

Review 8.  Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases.

Authors:  Kurinchi Selvan Gurusamy; Rajarajan Ramamoorthy; Dinesh Sharma; Brian R Davidson
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

9.  Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies.

Authors:  Rebecca M Dodson; Amin Firoozmand; Omar Hyder; Vania Tacher; David P Cosgrove; Nikhil Bhagat; Joseph M Herman; Christopher L Wolfgang; Jean-Francois H Geschwind; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2013-09-25       Impact factor: 3.452

10.  Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo.

Authors:  Koji Tsumagari; Zakaria Y Abd Elmageed; Andrew B Sholl; Erik A Green; Saboori Sobti; Abdul Razzaq Khan; Abdulrahman Kandil; Fadi Murad; Paul Friedlander; A Hamid Boulares; Emad Kandil
Journal:  Endocr Relat Cancer       Date:  2018-01       Impact factor: 5.900

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.